July 29, 2021 Portfolio News from ARCH Venture Partners | Share bluebird bio and National Resilience Ink Cell Therapy Strategic Alliance
July 26, 2021 Media Coverage from ARCH Venture Partners | Share ARCH adds FDA, biodefense expertise with appointment of Luciana Borio
July 22, 2021 Portfolio News from ARCH Venture Partners | Share Slingshot Launches with $23 Million for Synthetic Cell Products
July 19, 2021 Portfolio News from ARCH Venture Partners | Share Rome, backed by Arch and GV, hires science leaders to hit targets in “junk DNA”
July 14, 2021 Portfolio News from ARCH Venture Partners | Share Prime Medicine raises $315M to fuel ‘search-and-replace’ gene editing work
June 2, 2021 Media Coverage from ARCH Venture Partners | Share Global Business Reports: U.S. Pharmaceutical and Biopharmaceutical Industry Report. An interview with Keith Crandell.
May 15, 2021 Portfolio News from ARCH Venture Partners | Share ARCH Co-leads Investment for Interline, Precision Medicine Platform
April 28, 2021 Portfolio News from ARCH Venture Partners | Share New Antibody Therapy And Prophylactic Shows Promise In Defending Against SARS-CoV-2 Variants Of Concern
April 27, 2021 Portfolio News from ARCH Venture Partners | Share ARCH Leads Series A Round for Treeline Biosciences, New Cancer Biotech
April 20, 2021 Media Coverage from ARCH Venture Partners | Share Visualizing the Future: Spatialomics Transforms Study of Gene Expression
April 16, 2021 Media Coverage from ARCH Venture Partners | Share ARCH Venture Partners Named to Forbes’ Midas List 2021
April 15, 2021 Portfolio News from ARCH Venture Partners | Share ‘One Billion Doses On Day One’: Vaccine Company Resilience Claims World-Changing Innovation
